Diligence memo · auto-generated · as of July 2, 2026
AmbAgon Therapeutics Inc.
AmbAgon Therapeutics Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
AmbAgon Therapeutics Inc. operates in Biotechnology, based in Eindhoven.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
AmbAgon Therapeutics Inc. has raised $55M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2022-01-05.
Most recent recorded round closed around 2025-01-24.
Valuation (modeled)modeled
Provath models AmbAgon Therapeutics Inc. at approximately $36M (range $15M–$51M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.19× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 9.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).
Modeled value ranks above 39% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.